Genetic variations may influence weight-loss response to semaglutide
New research suggests that specific rare genetic variants in the GLP-1 receptor gene could significantly reduce the effectiveness of semaglutide for weight management.
A study published in Nature Metabolism has identified that individuals carrying certain rare variants of the GLP-1 receptor gene may experience significantly less weight loss when treated with semaglutide. Researchers analysed health records to determine how these genetic differences affect drug response, comparing outcomes between semaglutide and tirzepatide. The findings indicate that while these rare variants appear to attenuate the weight-loss effects of semaglutide, they do not seem to have the same impact on tirzepatide. The difference in response was notable, with carriers of these specific variants achieving only about one-quarter of the weight loss typically seen in patients without the variants. This research highlights the potential role of pharmacogenomics in understanding why some people respond differently to weight-loss medications. The study relied on observational data from insurance claims and prescription records to track weight changes over time. By comparing the efficacy of different GLP-1 receptor agonists in the context of a patient's genetic profile, the authors suggest that these rare variants could be a factor in the variability of clinical outcomes. It is important to note that this study is observational and does not prove that these genetic variants are the sole cause of the reduced response. Further research is required to confirm these findings and to understand the biological mechanisms involved. If you are concerned about your progress on a weight-loss medication, speak with your clinician to review your treatment plan and discuss whether your individual response is within expected ranges.
What it found
- Carriers of rare GLP1R variants achieved roughly 25% of the typical weight loss seen in non-carriers when using semaglutide.
- The study found no significant association between these specific rare variants and reduced weight loss when using tirzepatide.
What it can't tell us
This is an observational study based on health records, which cannot definitively prove that the genetic variants are the direct cause of the observed differences in weight loss.
If you're on it
If you feel your medication is not working as expected, discuss your progress with your doctor, as individual genetic factors may play a role in how you respond to different treatments.
Sources
Every brief is written from scratch. We summarise and link rather than reproducing anyone's article, abstract, table or image, and any direct quote is short and attributed. Read the original before you draw conclusions from a summary — including ours. Not medical advice. If something feels wrong, speak to a clinician or call 111.